Multiomics in Drug Discovery Market to Reach USD 1,447.23 Million by 2034, Growing at a CAGR of 17.08%

According to a new report published by Polaris Market Research, the global Multiomics in Drug Discovery Market was valued at USD 350.05 million in 2025 and is projected to reach USD 1,447.23 million by 2034, expanding at a CAGR of 17.08% during the forecast period.

Market Overview
The market has witnessed steady growth in recent years, driven by the growing utilization of integrated omics data for target identification, rising investment in precision medicine, and expanding adoption of AI-powered analytics across pharmaceutical research. Growing collaboration between sequencing technology providers, bioinformatics developers, and pharmaceutical companies is accelerating the shift toward genomics, transcriptomics, proteomics, and metabolomics data integration. Market participants are prioritizing single-cell and spatial profiling and strategic partnerships to strengthen their positioning, and demand is expected to remain resilient through the forecast period.

👉Explore the Research Before You Buy → Request a Sample:
https://www.polarismarketresearch.com/industry-analysis/multiomics-in-drug-discovery-market

Key Market Insights
• The market was valued at USD 350.05 million in 2025 and is projected to reach USD 409.21 million in 2026, reflecting rising adoption of integrated omics platforms for early-stage drug discovery.
• North America led the market with a 41.36% share in 2025, while Asia Pacific is expected to register the fastest regional growth through 2034.
• Growing use of single-cell and spatial profiling technologies is reshaping cellular-level research, with this segment projected to expand at the fastest CAGR of 18.94% during the forecast period.
• Competitive activity remains strong, with sequencing and bioinformatics providers pursuing AI-driven partnerships and platform expansions to strengthen market share.
• Rising regulatory support for biomarker qualification programs and federated genomic data platforms is reinforcing demand across major economies.

Market Dynamics
• Driver: Increasing adoption of integrated omics technologies for target identification and disease biology research.
• Driver: Rising use of AI-powered analytics and cloud-based bioinformatics platforms to accelerate biomarker discovery.
• Opportunity: Regulatory support, including biomarker qualification frameworks and national genomics initiatives, is easing pathways for precision-medicine research.
• Restraint: Complex data integration across multiple analytical systems, combined with high infrastructure and bioinformatics costs, limits adoption among smaller organizations.
• Restraint: A shortage of multidisciplinary professionals skilled in molecular biology, bioinformatics, and AI slows implementation timelines.
• Opportunity: Expansion of large-scale, federated biological databases is enabling secure collaborative research between pharmaceutical firms and research institutions.
• Opportunity: Growing investment in single-cell and spatial profiling is opening new avenues for solution providers.

Market Segmentation
The market is segmented based on offering, omics modality, application, and region. By offering, the products category held the largest share at 45.82% in 2025 on demand for sequencing instruments, while the software and data segment is projected to post the fastest growth as companies consolidate genomics, proteomics, and clinical datasets onto unified, AI-enabled platforms. By omics modality, genomics led with a 34.67% share in 2025, while single-cell and spatial profiling is set to expand fastest as researchers study individual cells and tissue structures. By application, target discovery held the largest share at 38.25% in 2025, while biomarker discovery is expected to see the strongest growth. Regionally, the market spans North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, each shaped by distinct research investment and regulatory conditions.

👉Get the Insights You Need to Plan Your Next Business Move:
https://www.polarismarketresearch.com/industry-analysis/multiomics-in-drug-discovery-market/pricing

Regional Insights
• North America: Held the leading position with a 41.36% share in 2025, supported by strong pharmaceutical research activity, advanced sequencing infrastructure, and high investment in precision medicine.
• Asia Pacific: Projected to register the fastest growth through 2034 as China, Japan, India, and South Korea expand pharmaceutical R&D spending and sequencing capabilities.
• Europe: Maintained a considerable share in 2025, driven by genomics research funding, pharmaceutical innovation, and expanding federated genomic data initiatives across Germany, the UK, and France.
• Latin America & Middle East and Africa: Emerging markets supported by growing clinical research activity, biotechnology infrastructure investment, and national healthcare modernization programs.

Competitive Landscape
The market is moderately fragmented, with key players focusing on AI-enabled analytical platforms and strategic partnerships to strengthen their market position. Leading companies continue investing in advanced, cost-efficient sequencing and bioinformatics solutions, while product launches, acquisitions, and collaborations remain common strategies for expanding geographic presence and market share. Some of the key players operating in the market include Illumina Inc., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Bruker Corporation, and QIAGEN N.V., among others.

Recent Developments
• July 2026: Illumina expanded its Billion Cell Atlas program, adding new AI drug discovery partners to advance single-cell multiomics research.
• May 2026: QIAGEN collaborated with NVIDIA to integrate graph-based AI and curated bioinformatics knowledge to accelerate drug target and biomarker discovery.
• November 2025: Athos Therapeutics partnered with Xeptiva Therapeutics to apply its AthosOmics AI multiomics platform to biomarker discovery and vaccine development.
• October 2025: Illumina launched BioInsight, a dedicated AI informatics business built for multiomic drug discovery and large-scale sequencing data integration.
• September 2025: Biognosys expanded its multiomics portfolio with new metabolomics and lipidomics services to support drug discovery and clinical research.

More Trending Latest Reports By Polaris Market Research:
Direct-To-Consumer Testing Market:
https://www.polarismarketresearch.com/industry-analysis/direct-to-consumer-testing-market

Osteoarthritis Injectable Market:
https://www.polarismarketresearch.com/industry-analysis/osteoarthritis-injectable-market

Single-Use Filtration Assemblies Market:
https://www.polarismarketresearch.com/industry-analysis/single-use-filtration-assemblies-market

AI in Neurology Market:
https://www.polarismarketresearch.com/industry-analysis/ai-in-neurology-market

Contact Us
Polaris Market Research & Consulting, Inc.
8 The Green Ste 19824, Dover, DE 19901, United States
Phone: +1 929-297-9727
Email: sales@polarismarketresearch.com
Web: www.polarismarketresearch.com

About Polaris Market Research & Consulting, Inc.
Polaris Market Research is a global market intelligence and consulting company dedicated to delivering in-depth business insights and actionable research. We specialize in providing syndicated reports, customized consulting solutions, and strategic advisory services across diverse industries including healthcare, chemicals, energy, automotive, technology, and consumer goods. Our research methodology combines quantitative data with qualitative expertise, ensuring our clients receive accurate market sizing, growth forecasts, competitive analysis, and emerging trend insights. With a commitment to transparency, data accuracy, and client satisfaction, Polaris Market Research has become a trusted partner to leading corporations, consulting firms, and government organizations worldwide. We help businesses make informed strategic decisions, mitigate risk, and identify new growth opportunities in rapidly evolving markets. Learn more at www.polarismarketresearch.com

This release was published on openPR.